Overview

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Status:
Terminated

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese subjects who are at a higher risk of having these events because they have diabetes and/or other cardiovascular risk factors.

Phase:

Phase 3

Details

Lead Sponsor:

Orexigen Therapeutics, Inc

Treatments:

Bupropion
Bupropion hydrochloride, naltrexone hydrochoride drug combination
Naltrexone